Skip to main content
OpenTrials
Completed

NCT Number: NCT05186805

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Eczema Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

2 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Dermavant Investigative Site, Calgary, Alberta, Canada

Loading trial locations.

About this study

This is a 4-week open-label study in which subjects will be assigned to receive tapinarof cream, 1% once daily for 4 weeks. At the end of the 4-week study treatment, qualified subjects will have the option to enroll in an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects who do not participate in the open-label, long-term extension study will complete a follow-up visit approximately one week after the end of treatment in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female subjects age 2 to 17 with a confirmed clinical diagnosis of atopic dermatitis and present for at least 6 months for ages 6-17 years old, 3 months for ages 2-5 years old
  • BSA involvement ≥ 25% for subjects ages 12-17 years old, or ≥ 35% for subjects ages 2-11 years old, suitable for topical therapy.
  • vIGA-AD score of ≥ 3 at screening and baseline (pre-dose)
  • Female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
  • Capable of giving written informed consent
  • Negative pregnancy test at Baseline (Day 1)

Exclusion criteria

  • Immunocompromised at screening
  • Chronic or acute systemic or superficial infection requiring treatment with systemic antibacterials or antifungals within one week prior to baseline visit
  • Significant dermatological or inflammatory condition other than AD that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper limit of normal (ULN).
  • Screening total bilirubin > 1.5x ULN
  • Current or chronic history of liver disease
  • Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects who would not be considered suitable for topical therapy
  • Use of any prohibited medication or procedure within the indicated period before the baseline visit including other investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer)
  • History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's participation in the study, interpretation of results, or ability to understand and give informed consent.
  • Pregnant or lactating females
  • History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the -Investigator or Medical Monitor, contraindicates their participation
  • Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)

Treatment and study plan

tapinarof cream, 1%

Drug

Tapinarof cream, 1% applied topically once daily

Other names: DMVT-505

Primary outcomes

  1. Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline to Day 28 for subjects enrolling in Long-Term Extension (LTE), otherwise to Day 35

    Number of Participants that Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs).

  2. Change From Baseline in Laboratory Values (U/L)

    Time frame: Baseline to Day 28

    Change in laboratory values was assessed for clinical relevance

  3. Change From Baseline in Laboratory Values (g/L)

    Time frame: Baseline to Day 28

    Change in laboratory values was assessed for clinical relevance

  4. Change From Baseline in Laboratory Values (mmol/L)

    Time frame: Baseline to Day 28

    Change in laboratory values was assessed for clinical relevance

  5. Change From Baseline in Laboratory Values (Umol/L)

    Time frame: Baseline to Day 28

    Change in laboratory values was assessed for clinical relevance

  6. Change From Baseline in Laboratory Values (10^9 Cells/L)

    Time frame: Baseline to Day 28

    Change in laboratory values was assessed for clinical relevance

  7. Change From Baseline in Laboratory Values (%)

    Time frame: Baseline to Day 28

    Change in laboratory values was assessed for clinical relevance

  8. Change From Baseline in Laboratory Values (pg)

    Time frame: Baseline to Day 28

    Change in Ery. mean corpuscular hemoglobin laboratory values was assessed for clinical relevance

  9. Change From Baseline in Laboratory Values (fL)

    Time frame: Baseline to Day 28

    Change in Ery. mean corpuscular volume laboratory values was assessed for clinical relevance

  10. Change From Baseline in Laboratory Values (10^12 Cells/L)

    Time frame: Baseline to Day 28

    Change in Erythrocytes laboratory values was assessed for clinical relevance

  11. Change From Baseline in Laboratory Values (L/L)

    Time frame: Baseline to Day 28

    Change in Hematocrit laboratory values was assessed for clinical relevance

  12. Mean Change in Local Tolerability Scale (LTS)

    Time frame: Baseline to Day 28

    Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale. 0 indicates no irritation and 4 indicates Very Severe irritation.

  13. Tapinarof Plasma PK Parameters on Day 1: AUC0-τ

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

    The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.

  14. Tapinarof Plasma PK Parameters on Day 1: Cmax

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

    The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.

  15. Tapinarof Plasma PK Parameters on Day 1: Tmax

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

    The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.

  16. Tapinarof Plasma Concentration: Cτ

    Time frame: Day 1 (PK samples collected pre-dose and at 1, 3, and 5 hours post-dose)

    The Cτ is a pharmacokinetic parameter that is the last quantifiable concentration determined directly from individual concentration-time data

  17. Change From Baseline in Vital Signs (Beats/Min)

    Time frame: Baseline to Day 28

    Change in pulse vital signs was assessed for clinical relevance

  18. Change From Baseline in Vital Signs (mmHg)

    Time frame: Baseline to Day 28

    Change in Blood Pressure vital signs was assessed for clinical relevance

  19. Change From Baseline in Vital Signs (C)

    Time frame: Baseline to Day 28

    Change in Temperature vital signs was assessed for clinical relevance

Secondary outcomes

  1. Change From Baseline in Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)

    Time frame: Baseline to Day 28

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

  2. Number of Subjects Who Have a Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Score of Almost Clear (0 or 1) and at Least a 2-grade Reduction From Baseline

    Time frame: Baseline to Day 28

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

  3. Number of Subjects With ≥50%, Improvement in Eczema Area and Severity Index (EASI) Score

    Time frame: Baseline to Day 28

    The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

  4. Number of Subjects With ≥75%, Improvement in Eczema Area and Severity Index (EASI) Score

    Time frame: Baseline to Day 28

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

  5. Number of Subjects With ≥90%, Improvement in Eczema Area and Severity Index (EASI) Score

    Time frame: Baseline to Day 28

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

  6. Mean Change in Eczema Area and Severity Index EASI From Baseline to Day 28

    Time frame: Baseline to Day 28

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

  7. Percent Change in Eczema Area and Severity Index EASI From Baseline to Day 28

    Time frame: Baseline to Day 28

    The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

  8. Mean Change in Percent of Total Body Surface Area (%BSA) Affected

    Time frame: Baseline to Day 28

    The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

  9. Percent Change in Percent of Total Body Surface Area (%BSA) Affected

    Time frame: Baseline to Day 28

    The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

  10. Mean Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values

    Time frame: Baseline to Day 28

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting (0 indicates no inflammatory signs of atopic dermatitis and 4 indicates disease is widespread). The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. %BSA is a static assessment made without reference to previous scores and will be evaluated 0-100%. The computation is referenced below, and no unit is applicable for this outcome measure. A negative change indicates improvement in disease.

    [Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)]

  11. Percent Change in Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD) Values

    Time frame: Baseline to Day 28

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Score of 0 indicates no inflammatory signs of atopic dermatitis and a 4 indicates disease is widespread in extent. The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

    Computation: Total Body Surface Area (BSA) x Validated Investigator Global Assessment in Atopic Dermatitis (vIGA-AD)

  12. Mean Change in Average Weekly Peak Pruritus Numerical Rating Scale (PP-NRS) Score

    Time frame: Baseline to Day 28

    The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.

  13. Proportion of Subjects With a Baseline Peak Pruritus Numerical Rating Scale (PP-NRS) Score ≥4 Who Achieved ≥4-point Reduction in PP-NRS Score

    Time frame: Baseline to Day 28

    The PP-NRS is a scale from 0-10 used to assess itch/pruritus severity over a 24-hour period which will be used daily to assess peak pruritus. Higher PP-NRS ratings represent more itch reported.

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 11, 2022
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.